Today: 31 January 2026
Subscribe
Browse Category

Earnings Reports News 4 November 2025 - 5 November 2025

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Financial Health and Earnings Trends Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quarters Investing, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY (1% in constant currency) to $4.48 B Investing, while adjusted earnings jumped…
5 November 2025
····
Axon Enterprise (AXON) Stock Plunges on Earnings Miss – What’s Next for the Taser Maker?

Axon Enterprise (AXON) Stock Plunges on Earnings Miss – What’s Next for the Taser Maker?

Stock Price and Recent Performance (as of Nov 5, 2025) Axon’s stock has experienced whiplash in early November. After closing at $706.13 on Nov 4 Stockanalysis, shares tumbled to around $563 in pre-market trading the next day Stockanalysis. This ~20% drop followed the company’s Q3 earnings announcement, where profits disappointed Wall Street. In fact, Axon’s stock had already been sliding…
5 November 2025
····
Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

In summary, Humana Inc. faces a pivotal moment: it’s balancing short-term earnings headwinds from elevated costs and rating setbacks against strong long-term fundamentals in the Medicare Advantage space. The latest news (Q3 beat and improved membership outlook) provides some relief that management’s corrective actions are working Reuters Reuters. However, caution prevails as 2026 looms without guidance and with likely flat…
5 November 2025
····
Lemonade (LMND) Stock Soars on Q3 Beat – Is Insurtech Growth Sustainable?

Lemonade (LMND) Stock Soars on Q3 Beat – Is Insurtech Growth Sustainable?

Recent News: Q3 Results and Market Reaction On Nov. 5, 2025 after market-close, Lemonade released its Q3 financials, and the stock surged. Both press coverage and company statements highlighted robust top-line growth and improving loss metrics. For example, Investing.com reported revenue +42% YOY to $194.5M (well above the ~$184–185M expected) and a narrower-than-forecast loss of $0.51 per share Investing. It noted…
5 November 2025
···
Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Stock Performance & Valuation Zeta’s stock has trended down from its late-2024 highs (~$36.7) as broader growth-tech valuation pressures emerged. At the Nov 4 close, ZETA was ~$16.70 Stockanalysis, near its 52-week low and well below its peak. Over the year it’s down ~–7% Marketbeat (since start-2025), while smaller tech peers have also lagged. On Nov 4 its volume was…
4 November 2025
···
Rivian Slashes 600 Jobs as EV Demand Slumps – Stock Hits & Experts Sound Alarm

Rivian Rally or Risk? EV Start-up Stock Jumps on Q3 Beat, Layoffs & R2 Hype

Key Facts: Rivian’s stock (NASDAQ: RIVN) closed around $13 on Nov. 4, 2025 (52-week range ~$9.50–$17.15 Stockanalysis), giving it a market cap of about $15.2 billion Stockanalysis. In Q3 2025 Rivian delivered 13,201 vehicles (highest quarter of 2025) and reported $1.558 billion in revenue, up 78% year-over-year Businesswire. Adjusted gross profit turned positive ($24 M) for the quarter Businesswire. Management kept…
4 November 2025
···
Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Enterprise Rockets Past Revenue Goals – But EPS Miss Sends Stock Reeling

Q3 2025 Earnings Report Axon’s Q3 results (announced Oct. 31) beat revenue expectations but showed a small profit shortfall. The company “delivered another record quarter, with revenue growing 31% year over year to $711 million” Prnewswire, marking its seventh straight quarter above 30% growth. Sales growth was driven by the software business – Axon’s Software & Services segment grew 41%…
4 November 2025
···
OpenAI’s AMD Mega-Deal Sparks an AI “Mega-Blob” – 6GW of Chips, a 10% Stake, and a $100B Bet

AMD’s Q3 2025 Earnings Shock: Record Sales and AI Boom Propel Stock to New Highs

Record Q3 Results and Financials AMD’s Q3 2025 report (released Nov 4) shattered records. The company posted $9.246 billion in revenue, up 36% from a year ago Amd. GAAP earnings were $1.243 billion (EPS $0.75), and non-GAAP earnings $1.965 billion (EPS $1.20) Amd. This beat analysts’ expectations (roughly $8.7–8.8 B revenue, $1.17 EPS consensus) by a comfortable margin. The growth was led by AMD’s…
4 November 2025
··
Reddit’s Stock Explodes! 78% Revenue Surge, Google AI Deal Talks & 70% Rally 🔥

Reddit’s Stock Soars on Blowout Earnings – 7 Must-Know Facts for Investors

Latest News and Developments In early November 2025, Reddit Inc. is making headlines for its stellar third-quarter performance and the market’s reaction to it. The company announced Q3 2025 results on October 30, delivering growth figures that impressed investors and analysts alike. Reddit’s revenue for the quarter jumped 68% year-over-year to $585 million, well above consensus estimates (~$547 M) Marketbeat. Net income came…
4 November 2025
····
Xometry (XMTR) Stock Soars on Record Q3 Earnings – What’s Next for This AI Manufacturing Marketplace?

Xometry (XMTR) Stock Soars on Record Q3 Earnings – What’s Next for This AI Manufacturing Marketplace?

Key Facts (as of Nov 4, 2025) Stock Price & Recent Performance Xometry’s stock (NASDAQ: XMTR) has been on a tear in early November 2025. On Nov 4, 2025, shares skyrocketed ~24% intraday following the Q3 earnings announcement, peaking around $60 and nearing a 52-week high of $60.68 Ainvest. It closed the day at roughly $60.23 (up from $48.57 the…
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week range ($20.92 – $28.00) Marketbeat. The stock hit a 12-month low just above $20 in early 2025 amid…
4 November 2025
····
Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Stock Price and Performance History Axcelis stock traded in the mid-$80s in early November 2025, rallying on earnings news. It closed around $86.24 on Nov 4, 2025, up about 5% for the day and roughly 8–9% over the two sessions surrounding its earnings report. This rebound comes after a soft October where ACLS had slid ~14% over a month Nasdaq,…
4 November 2025
····
1 … 264 265 266 267 268 … 286

Stock Market Today

  • Deckers Stock Surges 19% After Q3 Beat, Up Nearly 10,000% Since IPO
    January 31, 2026, 12:25 AM EST. Deckers (DECK) shares jumped nearly 19% after beating third-quarter earnings expectations, fueled by strong sales of its Hoka and Ugg brands. The footwear maker reported 7.1% revenue growth to $1.96 billion and a 11% rise in earnings per share to $3.33, surpassing consensus estimates. Management raised full-year guidance with revenue forecast between $5.4 billion and $5.425 billion, driven by solid growth in both wholesale and direct-to-consumer channels. Despite a 46% dip over the past year amid inflation and weak spending, Deckers has gained roughly 9,660% since its 1993 IPO, more than doubling Nike's returns. The company's diverse product line and recovered international sales signal potential for further stock appreciation.
Go toTop